Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

by admin July 26, 2024
July 26, 2024
Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024.

As announced on 14 February 2023, the Company initiated the process to obtain a secondary listing on the Nasdaq Capital Market. Due to market conditions, the Company subsequently delayed the process.

As announced on 25 June 2024, as part of a A$70 million capital raising, the Company agreed with certain US institutional investors to seek a listing of its ordinary shares in the form of American Depositary Shares on Nasdaq by the end of 2024.

Yesterday the Company filed an amendment to its registration statement on Form 20-F with the US Securities and Exchange Commission (SEC) and is continuing to progress a listing application with Nasdaq. The Company expects the SEC and Nasdaq to complete their respective review processes by late August and, when their processes are successfully completed, then the listing on Nasdaq would occur.

The Nasdaq listing will take the form of a Level 2 American Depositary Receipt program, with each American Depositary Share representing 200 ordinary shares, and will not involve the raising of any capital. The American Depositary Shares (ADS) are expected to trade on Nasdaq under the ticker RADX. Deutsche Bank Trust Company Americas will be appointed by the Company as depositary, custodian and registrar of the ADS.

The Nasdaq listing will complement the existing primary listing of RAD shares on the Australian Securities Exchange (ASX) with minimal additional administration. Ordinary shares are currently listed on the ASX under the RAD symbol where they will continue to trade following the Nasdaq listing.

‘We are confident that obtaining a listing on Nasdaq will complement our loyal existing Australian shareholder base by expanding Radiopharm’s access to investors globally, and thereby drive increased shareholder value with enhanced liquidity for all shareholders,’ said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.

This program is part of an ongoing strategy to expand the Company’s reach to US institutional and retail investors by enabling them to purchase the Company’s shares via a US stock market, in the American time zone and in US dollars.

The review process by the SEC in relation to the registration statement and by Nasdaq in relation to the listing application continues to be in progress. There can be no assurance as to the completion or timing of this process or such a listing.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Melodiol Global Health
next post
Cyprium and Glencore Announce Commercial Strategic Partnership

Related Posts

Seismic Disruptions Could Cost Copper and Rhenium Industries...

July 20, 2024

Sarama Completes Tranche 2 Options Placement

February 11, 2025

High Grade discoveries with enriched MREOs at Agostinho...

February 5, 2025

Top 3 Canadian Nickel Stocks of 2024

August 7, 2024

Stardust Power Inc. Announces Pricing of $5.75 Million...

January 25, 2025

Spectacular Vein Gold Discovery Expands Christmas Gift Shear

May 14, 2024

Syntheia Provides Telemarketer Services for Political Campaign in...

April 12, 2025

Two Water Wells Completed & Staking Finalised at...

January 30, 2025

R&D Tax Refund of $7.9M Received

November 11, 2024

Is Trump a Threat to US Electric Vehicle...

November 1, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Find Highest Probability Counter-Trend Setups

      June 26, 2025
    • Bernie Moreno wants Senate to call for Nobel Peace Prize to go to Trump

      June 26, 2025
    • Iran, Israel and US agree that Islamic Republic nuclear sites were ‘badly damaged’ despite leaked intel report

      June 26, 2025
    • UN’s atomic agency’s Iran policy gets mixed reviews from experts after US-Israel ‘obliterate’ nuclear sites

      June 26, 2025
    • Democratic congressman hurls profanity-laced message at Stephen Miller

      June 26, 2025

    Categories

    • Business (997)
    • Investing (2,471)
    • Politics (3,067)
    • Stocks (1,095)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved